Cellomics and BD Biosciences sign license agreement
PITTSBURGH—Cellomics, Inc. and global medical technology company BD through its BD Biosciences unit, announced this month a non-exclusive, worldwide patent license agreement that provides BD with Cellomics' core high–content screening patent portfolio that includes both broad claims to HCS technology and specific classes of HCS assays.
"With the recent acquisition of Atto Bioscience, and our licensing of this intellectual property from Cellomics, BD Biosciences extends our commitment to the area of high-content cellular analysis and strengthens our considerable capabilities in the area of live cell research," says Mark Lewis, vice president of BD Biosciences.
ALA elects directors
CHICAGO—The Association for Laboratory Automation (ALA), recently elected three members to its Board of Directors. Re-elected was Peter Grandsard, Ph.D., of Amgen. Grandsard has been a member of the ALA since 1996. Newly elected board members are Andrea W. Chow, Ph.D. a vice president for microflidics R&D with Caliper Life Sciences and Professor Reinhold Schaeferm Dr, rer, nat., of the University of Weisbaden, Germany.
"The additions of Andrea Chow and Reinhold Schaefer further diversify our Board," says Grandsard. "I am confident that having them on the Board will further the advancement of the ALA as the premier professional society of automation and instrumentation technologists."
ComGenex provides platform technologies to Roche
BUDAPEST, Hungary—ComGenex Inc. announced in early January the successful completion of a research agreement with Roche in the area of high-throughput medicinal chemistry. Under the terms of the agreement, Roche used ComGenex platform technologies to support internal lead generation for drug discovery and development programs.
Applying its proprietary ComGenex Matrix Technology, ComGenex used in silico tools to expedite the design of targeted compound libraries and also synthesized and purified the compounds using its high-throughput synthesis and purification platforms for biological evaluation at Roche.
